2c:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/1bqb83_yclja0.js","/_next/static/immutable/chunks/0g_m72sf-uhff.js","/_next/static/immutable/chunks/30t4sjq-27eg7.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/32zk736rs0hqw.js","/_next/static/immutable/chunks/0lbgs964whs_0.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js","/_next/static/immutable/chunks/0hcnvyarhzl7i.js"],"default"] 2d:T62d3,

Summary Table

Category	Details
Risk Factors	Travel to or residence in the Arabian Peninsula (especially Saudi Arabia); direct/indirect contact with dromedary camels; healthcare workers in endemic regions; older adults (median age ~50); males; comorbidities (diabetes mellitus, chronic kidney disease, chronic heart disease, chronic lung disease, immunosuppression)
Etiology	MERS-CoV, a positive-sense single-stranded RNA betacoronavirus. Zoonotic reservoir: dromedary camels. Enters human cells via the dipeptidyl peptidase 4 (DPP4/CD26) receptor
Patient Presentation	Fever, cough, and dyspnea developing over days. Rapid progression to severe pneumonia and respiratory failure. Gastrointestinal symptoms (diarrhea, vomiting, abdominal pain) in roughly one-third of patients. Asymptomatic or mild upper respiratory illness in a subset
Classic Physical Exam	Fever (may be absent in elderly, immunosuppressed, or very young), tachypnea, bilateral crackles/rales, signs of respiratory distress, hypoxia. In advanced cases: signs of septic shock, multi-organ failure
Key Diagnostic Results	Screening: rRT-PCR targeting the upE gene from lower respiratory tract specimens. Confirmation: rRT-PCR targeting ORF1a or N gene. Labs: lymphopenia, leukopenia, thrombocytopenia, elevated LDH. CXR: bilateral ground-glass opacities (GGO), consolidation with lower-lobe predominance. CT: GGO, consolidation, air bronchograms, crazy-paving pattern
Management	No approved antiviral therapy. Supportive care is the cornerstone: supplemental oxygen, mechanical ventilation for ARDS, hemodynamic support, renal replacement if needed. Investigational: ribavirin + interferon-alpha2a/2b or lopinavir/ritonavir + interferon-beta1b (limited evidence). Strict infection control with airborne, contact, and standard precautions
Keywords	"Traveled to Saudi Arabia," "contact with camels," "rapidly progressive pneumonia," "renal failure with respiratory failure," "DPP4 receptor," "bilateral GGO," "healthcare-associated outbreak," "36% case fatality rate"

1. Pathophysiology

MERS-CoV is a lineage C betacoronavirus that was first isolated in Saudi Arabia in 2012. As of mid-2025, roughly 2,627 laboratory-confirmed cases and around 943 associated deaths have been reported globally, yielding a case fatality rate of approximately 36%. The overwhelming majority of cases have been reported from Saudi Arabia.

The virus's natural reservoir is the dromedary camel. Seroepidemiological studies show that nearly all adult camels in the Arabian Peninsula and Africa carry antibodies to MERS-CoV, reflecting long-standing endemic circulation. Human infection occurs through direct or indirect contact with infected camels (nasal secretions, milk, meat, urine, feces) or, less efficiently, through human-to-human transmission in close-contact or healthcare settings.

The cellular entry mechanism is central to understanding why MERS looks the way it does clinically. MERS-CoV uses its spike (S) glycoprotein to bind to dipeptidyl peptidase 4 (DPP4, also known as CD26), a transmembrane receptor expressed on the surface of epithelial cells in the lower respiratory tract, renal tubular cells, intestinal epithelium, liver cells, and immune cells including macrophages and T lymphocytes. This broad receptor distribution is the reason MERS produces not only pneumonia but also extrapulmonary organ damage, notably acute kidney injury, which is a distinguishing feature compared to other coronavirus infections.

Once the virus enters the cell, it replicates and triggers a dysregulated host immune response. Infection of macrophages via the S protein-DPP4 interaction suppresses their capacity to produce pro-inflammatory cytokines (TNF-alpha, IL-6) while augmenting production of the immunosuppressive cytokine IL-10. This immune evasion allows the virus to replicate unchecked in its early stages. Eventually, the host mounts a delayed but exaggerated inflammatory response, resulting in a cytokine storm, diffuse alveolar damage, and ARDS. The diffuse alveolar damage is the pathological substrate for the bilateral ground-glass opacities and consolidation seen on imaging.

The renal tropism of MERS-CoV is a high-yield concept. DPP4 is expressed on kidney epithelial cells, and acute renal failure in MERS patients occurs earlier (median onset around 11 days) than it did in SARS patients (around 20 days), suggesting that MERS-CoV may cause direct viral injury to the kidneys rather than purely secondary ischemic damage. This makes the combination of progressive respiratory failure plus acute kidney injury a signature pattern.

The incubation period is approximately 5 to 7 days (range 2 to 14 days). From the onset of illness to hospitalization, the median interval is roughly 4 days. Patients who require ICU admission often exhibit rapid progression from a febrile upper respiratory illness to pneumonia within one week.

2. Classification and Clinical Manifestation

Severity	Clinical Features	Typical Outcome
Asymptomatic / Subclinical	No symptoms; detected only through contact tracing or serosurveys	Full recovery; contributes to underascertainment of true incidence
Mild	Upper respiratory symptoms: fever, cough, sore throat, myalgia, mild malaise. Resembles influenza	Recovery without hospitalization in otherwise healthy individuals
Moderate (Pneumonia)	Fever, productive cough, dyspnea, hypoxia, bilateral infiltrates on CXR. GI symptoms (diarrhea, vomiting, abdominal pain) in ~33% of patients	Often requires hospital admission; may progress
Severe (ARDS / Multi-organ Failure)	Rapidly progressive pneumonitis, refractory hypoxemia, ARDS requiring mechanical ventilation, septic shock, acute kidney injury, hepatitis, DIC	ICU admission; high mortality; median time to ICU is 2 days from hospital admission

Clinical pearls to keep in mind:

GI symptoms (diarrhea, vomiting, abdominal pain) are present in roughly one-third of patients and may occasionally be the presenting complaint, especially in immunocompromised individuals.
Fever may be absent in the very young, the elderly, immunosuppressed patients, or those on antipyretics or certain medications. A vignette describing an afebrile pneumonia with travel history should still raise concern.
Healthcare-associated transmission is a well-documented pattern. Clusters in hospital settings, particularly dialysis units and ICUs, are repeatedly described in outbreak reports.

3. Diagnostic Workup

Test	Role	Target / Finding	Specimen
rRT-PCR (upE gene)	Best Initial / Screening Test	Upstream of envelope gene	Lower respiratory tract preferred (sputum, BAL, tracheal aspirate); NP swab acceptable if lower tract not available
rRT-PCR (ORF1a or N gene)	Confirmatory Test	Open reading frame 1a or nucleocapsid gene	Same specimen as screening
Serology (ELISA, IFA, microneutralization)	Epidemiological / retrospective; NOT diagnostic	Anti-MERS-CoV antibodies (paired sera, 14 days apart)	Serum
CBC	Supportive	Lymphopenia, leukopenia, thrombocytopenia	Blood
LDH, AST, ALT	Supportive	Elevated LDH (up to ~50% of cases); mildly elevated transaminases	Blood
Creatinine / BUN	Monitor for renal involvement	Elevated in acute kidney injury	Blood
CXR	First-line imaging	Bilateral GGO, consolidation; lower-lobe predominance; rapid progression	Chest radiograph
CT Chest	More sensitive than CXR	GGO, consolidation, air bronchograms, crazy-paving, interstitial thickening; peripheral and lower-lobe predominance	CT scan

The best initial test for a suspected MERS case is real-time reverse transcription PCR (rRT-PCR) targeting the upE gene. The WHO recommends screening for MERS-CoV using RT-PCR of the upstream envelope gene (upE), followed by confirmation with ORF1a, ORF1b, or the nucleocapsid (N) gene. This is a two-step diagnostic algorithm: a positive upE screening must be confirmed with a second, independent genomic target before the case is considered laboratory-confirmed.

Lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) carry a higher viral load than nasopharyngeal swabs and are preferred. If only upper respiratory specimens are available and the result is negative but clinical suspicion remains high, repeat testing or lower tract sampling should be pursued.

Laboratory findings at presentation may include leukopenia, lymphopenia, thrombocytopenia, and elevated lactate dehydrogenase levels, particularly as illness severity increases. These are nondiagnostic but supportive in the right clinical context. Renal function tests may reveal rising creatinine in cases progressing toward multi-organ failure.

Chest imaging is abnormal in more than 80% of hospitalized MERS cases. Ground-glass opacity is found in over 60% of chest radiographs, with consolidation in approximately 20%. The most common pattern seen on both CXR and CT is ground-glass opacities and consolidation with peripheral predominance, eventually spreading to involve both lungs as the disease progresses. Lower lobes tend to be affected more than upper lobes early in the course of illness, and the radiographic appearance can progress rapidly. CT may additionally show air bronchograms, crazy-paving pattern, and interstitial thickening. In severe cases, imaging is consistent with ARDS.

Serology (ELISA for S1 protein, immunofluorescence, microneutralization assays) is not used for acute diagnosis. It requires paired serum samples collected at least 14 days apart and is reserved for epidemiological surveillance, seroprevalence studies, and retrospective confirmation of past infection.

A key testing principle for exams: in a vignette with a returned traveler from the Arabian Peninsula presenting with severe pneumonia, the next best step is rRT-PCR from a lower respiratory specimen, not serology.

4. Management and Treatment

Phase	Intervention	Details
Acute Stabilization	Supplemental oxygen	Titrate to $SpO_2 \geq 90%$; consider high-flow nasal cannula, NIV, or early intubation for refractory hypoxemia
	Mechanical ventilation	Lung-protective ventilation strategy (low tidal volume $6\ mL/kg$ predicted body weight, plateau pressure $< 30\ cmH_2O$) for ARDS
	Hemodynamic support	IV fluids, vasopressors (norepinephrine first line) for septic shock
	Renal replacement therapy	For acute kidney injury meeting indications for dialysis
Investigational Antivirals	Ribavirin + IFN-alpha2a	Ribavirin dose adjusted by CrCl; pegylated IFN-alpha2a 180 mcg SC weekly x 2 weeks. Showed improved 14-day survival but NOT 28-day survival in one retrospective cohort
Investigational Antivirals	Lopinavir/ritonavir + IFN-beta1b	Under investigation (MIRACLE trial). In vitro and animal data suggest efficacy
Infection Control	Airborne + contact + standard precautions	N95 respirator (or equivalent), gown, gloves, eye protection. Negative-pressure isolation room. Strict hand hygiene
Monitoring	Serial labs, imaging	Daily CBC, renal/liver function, LDH. Repeat CXR to track progression. Continuous $SpO_2$ monitoring

Despite past efforts, there are still no licensed therapies of proven efficacy for MERS-CoV. Supportive measures remain the mainstay of treatment and include respiratory and circulatory support, preservation of renal, hepatic, and neurological function, and prevention of secondary infections.

Acute stabilization follows the principles of critical care for severe community-acquired pneumonia and ARDS. Oxygen therapy should be escalated as needed, moving from nasal cannula to high-flow oxygen to non-invasive ventilation and ultimately to intubation with lung-protective mechanical ventilation. Prone positioning may be considered for refractory hypoxemia, consistent with ARDS management protocols. Hemodynamic instability should be treated with fluid resuscitation and vasopressors.

Regarding investigational antivirals, the most studied combination is ribavirin plus interferon. In one retrospective cohort of patients with severe MERS-CoV infection, ribavirin and interferon alfa-2a therapy was associated with improved survival at 14 days, but not at 28 days. The ribavirin dosing is adjusted based on creatinine clearance and is typically given for 8 to 10 days. However, patients can experience significant toxicities including hemolytic anemia and metabolic abnormalities, making it difficult to assess whether the benefit outweighs the harm without randomized controlled trial data.

The MIRACLE trial investigated lopinavir/ritonavir combined with interferon-beta1b, with outcomes still limited in published evidence. This combination showed promising results in animal and in vitro studies. No definitive RCT has established an approved antiviral regimen for MERS.

Corticosteroids deserve special mention. Certain strategies have been shown to worsen clinical outcomes in the setting of coronavirus infections. Systemic corticosteroids are generally avoided in MERS because they may delay viral clearance and are associated with worse outcomes unless indicated for another condition (e.g., refractory septic shock per surviving sepsis guidelines). This is a frequent "trap" answer on exams.

Infection prevention is absolutely critical and commonly tested. MERS-CoV is transmitted via respiratory droplets and contact. In healthcare settings, airborne precautions (negative-pressure room, N95 respirator), contact precautions (gown, gloves), and standard precautions (hand hygiene, eye protection) are all required, especially during aerosol-generating procedures (intubation, suctioning, bronchoscopy, nebulization).

5. Differential Diagnosis and Distractors

Differential	Why It Is Similar	Key Discriminator
Severe Influenza (H1N1, H5N1, H7N9)	Fever, cough, dyspnea, bilateral infiltrates, lymphopenia, rapid progression to ARDS. Can also occur in travelers	No camel/Arabian Peninsula exposure. Influenza rapid antigen or PCR positive. Responds to oseltamivir. No prominent renal involvement early in course
SARS-CoV / SARS-CoV-2	Betacoronavirus causing severe pneumonia with bilateral GGO, lymphopenia, ARDS. Similar imaging patterns	Different receptor (ACE2 for SARS-CoV and SARS-CoV-2 vs. DPP4 for MERS-CoV). Different geographic risk (SARS-CoV: China 2003; SARS-CoV-2: global). MERS uniquely features early acute kidney injury. Confirmed by virus-targeted rRT-PCR
Legionella Pneumonia	Severe community-acquired pneumonia with diarrhea, renal dysfunction, elevated LDH, and bilateral infiltrates	Exposure to contaminated water systems (cooling towers, hotels), not camels. Legionella urinary antigen positive. Hyponatremia is classic. Responds to fluoroquinolones or macrolides
Pneumocystis jirovecii Pneumonia (PJP)	Bilateral GGO on imaging, dyspnea, hypoxia in immunocompromised patient	Occurs in severely immunocompromised (HIV with $CD4 < 200$, organ transplant). Insidious onset over weeks, not days. Elevated beta-D-glucan. Diagnosed by methenamine silver stain or PCR on BAL
Community-Acquired Bacterial Pneumonia	Fever, cough, dyspnea, consolidation on CXR	Typically lobar consolidation (not bilateral diffuse GGO). Productive purulent sputum. Leukocytosis with left shift (not lymphopenia). No travel/camel exposure. Responds to standard antibiotics
Hantavirus Pulmonary Syndrome	Rapid respiratory failure, bilateral infiltrates, thrombocytopenia	Exposure to rodent excreta (not camels). Southwestern US/Americas geography. Hemoconcentration, large left pleural effusion. No GI symptoms typically prominent. Serology positive for hantavirus

6. Traps and High-Yield Pearls

The single most common way students miss MERS questions is by failing to connect the geographic/exposure history to the diagnosis. A vignette will nearly always include a sentence about travel to the Arabian Peninsula or contact with dromedary camels. If you read "recently returned from Saudi Arabia" or "works at a camel farm" alongside severe pneumonia, MERS should immediately rise to the top of your differential, regardless of how generic the respiratory symptoms may appear.

A second frequent error is ordering serology as the initial diagnostic test. Serology is for epidemiological surveillance and requires paired sera weeks apart. The correct initial step is always rRT-PCR from a lower respiratory tract specimen. Additionally, students sometimes choose nasopharyngeal swabs over lower tract specimens. While NP swabs are acceptable when lower tract samples are unavailable, the vignette may test your understanding that lower tract specimens have higher sensitivity.

The acute kidney injury component is the clinical discriminator that separates MERS from other severe viral pneumonias. When a vignette describes concurrent pneumonia and rising creatinine early in the disease course, think MERS before other viral pneumonias. This is directly tied to the DPP4 receptor distribution on renal tubular epithelium.

Do not fall for the trap of selecting corticosteroids as part of the treatment regimen. Unlike some other conditions causing ARDS (such as COVID-19 where dexamethasone showed benefit), corticosteroids are generally not recommended for MERS and may worsen outcomes by prolonging viral shedding.

Finally, infection control is a commonly tested management step. In any question asking for the "next best step" after diagnosing or suspecting MERS in a hospitalized patient, placing the patient in airborne isolation with full personal protective equipment is a valid and sometimes the best answer, particularly if the question stem focuses on preventing nosocomial spread.

In short, the core competency being tested with MERS questions is your ability to recognize an epidemiologically linked severe pneumonia with extrapulmonary features (especially renal), confirm it with the correct molecular test from the correct specimen type, manage it supportively without harmful interventions, and implement appropriate infection control measures.

1d:["$","$L2c",null,{"article":{"id":"42200e06-5048-4ba8-9e4d-0b0ae7ee6286","title":"Middle East Respiratory Syndrome (MERS)","content":"$2d","category":"Respirologi","created_at":"2026-09-07T06:45:21.471451+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]